AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
230.69
-0.55 (-0.24%)
At close: Oct 9, 2025, 4:00 PM EDT
232.00
+1.31 (0.57%)
After-hours: Oct 9, 2025, 7:59 PM EDT
AbbVie Revenue
AbbVie had revenue of $15.42B in the quarter ending June 30, 2025, with 6.65% growth. This brings the company's revenue in the last twelve months to $58.33B, up 6.05% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$58.33B
Revenue Growth
+6.05%
P/S Ratio
6.99
Revenue / Employee
$1,060,509
Employees
55,000
Market Cap
407.53B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
ABBV News
- 18 hours ago - SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer - PRNewsWire
- 3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 3 days ago - AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor - PRNewsWire
- 6 days ago - AbbVie expects $2.7 billion R&D charge in third quarter - Reuters
- 6 days ago - AbbVie: Wins Accumulating While We Wait For Next BD Steps - Seeking Alpha
- 7 days ago - ABBV Stock vs. Eli Lilly & Merck - Forbes
- 7 days ago - AbbVie to Host Third-Quarter 2025 Earnings Conference Call - PRNewsWire
- 8 days ago - Natrelle® Awarded Supplier Agreement from Vizient - PRNewsWire